Churlaud, Guillaume http://orcid.org/0000-0003-1343-752X
Rosenzwajg, Michelle
Cacoub, Patrice
Saadoun, David
Valteau-Couanet, Dominique
Chaput, Nathalie
Pugliese, Alberto
Klatzmann, David
Funding for this research was provided by:
FP7 research grant (DIABIL-2 (number 305380))
NB-GD2 (DGOS: TRANSLA 12-109; INCA: 2012-057 and Cancérop)
Article History
Received: 31 January 2018
Accepted: 20 April 2018
First Online: 2 June 2018
Duality of interest
: MR, PC, DS and DK are inventors on a patent application related to the therapeutic use of ld-IL-2, which belongs to their academic institutions and has been licensed to ILTOO Pharma. MR, PC, GC and DK hold shares in ILTOO Pharma.